Chandrasekhar Udata

1.2k citations

36 papers · 895 indexed · h-index 14

Hematology top 5%
- Hemophilia Treatment and Research 5
Oncology top 10%
- Drug Transport and Resistance Mechanisms 4
Genetics top 10%
- Chronic Lymphocytic Leukemia Research 3
Radiology, Nuclear Medicine and Imaging top 10%
- Monoclonal and Polyclonal Antibodies Research 7
Immunology
- Biosimilars and Bioanalytical Methods 7
Pediatrics, Perinatology and Child Health
- Pharmaceutical studies and practices 6
Molecular Biology
- Amyloidosis: Diagnosis, Treatment, Outcomes 4
Epidemiology
- Neuroendocrine Tumor Research Advances 3

Co-authors: Meng Xu Arie Katz O. Vesterqvist Michael E. Burczynski Lisa Hickey Elyssa Ott David A. Roth John F. DiJoseph
Cited by: Hematology Oncology Genetics
Journals: Blood (7 papers)Gastroenterology (1 paper)Journal of the American College of Cardiology (1 paper)
Partner nations: United States United Kingdom New Zealand

In The Last Decade

Chandrasekhar Udata

35 papers receiving 870 citations

Peers

Countries citing papers authored by Chandrasekhar Udata

Since Specialization

Citations

This map shows the geographic impact of Chandrasekhar Udata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chandrasekhar Udata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chandrasekhar Udata more than expected).

Fields of papers citing papers by Chandrasekhar Udata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chandrasekhar Udata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chandrasekhar Udata. The network helps show where Chandrasekhar Udata may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Chandrasekhar Udata, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Chandrasekhar Udata Line = papers co-authored together Chandrasekhar Udata links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Prediction of Cardiac ATTR Depletion by NI006 (ALXN2220) Using Mechanistic PK/PD Modeling Clinical Pharmacology & Therapeutics ·Aubin Michalon,Lionel Renaud,Matthias Macháček,Cédric Cortijo,Chandrasekhar Udata,Michele F. Mercuri,Fabian Buller,Christoph Höck,Roger M. Nitsch,Peter C. Kahr,Jan Grimm	2024	1
2	S204: SAFETY AND TOLERABILITY OF CAEL-101, AN ANTI-AMYLOID MONOCLONAL ANTIBODY, COMBINED WITH ANTI-PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS: 18-MONTH RESULTS OF A PHASE 2 STUDY HemaSphere ·Jason Valent,Michaela Liedtke,Jeffrey A. Zonder,Maria Angelica Molina,Chandrasekhar Udata,Juliana Ianus,John Tripptree,Julia Catini,Cristina Quarta	2023	2
3	Model-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor-α, in Adults with Type 1 Diabetes The AAPS Journal ·Jason H. Williams,Chandrasekhar Udata,Bishu Ganguly,Samantha Bucktrout,Tenshang Joh,Megan B. Shannon,Gilbert Y. Wong,Matteo Levisetti,Pamela D. Garzone,Meng Xu	2020	10
4	Abstract 5508: BCMA-CD3 bispecific antibodies: A modeling framework to characterize kinetics of bispecific antibody, T cell, cytokines, and serum M-protein Cancer Research ·Chandrasekhar Udata,Dai Wei,Sibo Jiang,Alison Forgie,Andrea T. Hooper,Wenlian Qiao,Cynthia J. Musante,Donghua Yin	2020	0
5	Immunomodulatory activity of humanized anti–IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes JCI Insight ·Kevan C. Herold,Samantha Bucktrout,Xiao Wang,Bruce W. Bode,Stephen E. Gitelman,Peter A. Gottlieb,Jing W. Hughes,Tenshang Joh,Janet B. McGill,Jeremy Pettus,Shobha Potluri,Desmond Schatz,Megan B. Shannon,Chandrasekhar Udata,Gilbert Y. Wong,Matteo Levisetti,Bishu Ganguly,Pamela D. Garzone	2019	27
6	Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial Endocrine ·Barry Gumbiner,Brooke Esteves,Vanessa Dell,Tenshang Joh,Pamela D. Garzone,Alison Forgie,Chandrasekhar Udata	2018	13
7	A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01) Expert Review of Clinical Immunology ·Ramesh Palaparthy,Chandrasekhar Udata,Steven Y. Hua,Donghua Yin,Chun‐Hua Cai,Stephanie Salts,Muhammad I. Rehman,Joseph E. McClellan,Meng Xu	2018	23
8	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects Clinical Therapeutics ·Hong Wan,Barry Gumbiner,Tenshang Joh,Tom Riel,Chandrasekhar Udata,Philippe Forgues,Pamela D. Garzone	2017	10
9	Mo1221 Comparative Assessments of PF-06438179, a Potential Biosimilar, and Infliximab in a Phase 1 Pharmacokinetic Study Gastroenterology ·Donghua Yin,Chandrasekhar Udata,Steven Y. Hua,Stephanie Salts,Meng Xu,Theodore R. Johnson,Mazin Derzi,Hugh D. Conlon,Carol F. Kirchhoff,Muhammad Rehman	2015	3
10	EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2ΔA MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS Journal of the American College of Cardiology ·Hong Wan,Barry Gumbiner,Tenshang Joh,Chandrasekhar Udata,Philippe Forgues,Pamela D. Garzone	2013	4
11	Population Pharmacokinetic Modeling of Pantoprazole in Pediatric Patients From Birth to 16 Years The Journal of Clinical Pharmacology ·William Knebel,Brinda Tammara,Chandrasekhar Udata,Gail M. Comer,Marc R. Gastonguay,Meng Xu	2010	21
12	Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII Haemophilia ·Michael Recht,László Nemes,Michał Matysiak,Marilyn J. Manco‐Johnson,Jeanne M. Lusher,Mark P. Smith,P.M. Mannucci,C. R. M. Hay,Thomas C. Abshire,Amanda C. O’Brien,Brooke Hayward,Chandrasekhar Udata,David A. Roth,Steven Arkin	2009	67
13	Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy Participants The Journal of Clinical Pharmacology ·Arie Katz,Chandrasekhar Udata,Elyssa Ott,Lisa Hickey,Michael E. Burczynski,Peter H. Burghart,O. Vesterqvist,Meng Xu	2009	151
14	ReFacto®¹ and Advate®²: a single‐dose, randomized, two‐period crossover pharmacokinetics study in subjects with haemophilia A Haemophilia ·(unknown),Mark P. Smith,Robert Klamroth,P.M. Mannucci,Carl Kollmer,J. Feingold,C. M. Kessler,H. Pöllmann,Massimo Morfini,Chandrasekhar Udata,C. Rothschild,Cédric Hermans,Robert L. Janco	2007	39
15	Reformulated BeneFix^®: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B Haemophilia ·Thierry Lambert,Michael Recht,Leonard A. Valentino,Jerry S. Powell,Chandrasekhar Udata,S. T. SULLIVAN,David A. Roth	2007	76
16	PIII-70Ascending single dose study of the safety, tolerability, and pharmacokinetics of rotigaptide (ZP123) administered intravenously to healthy subjects Clinical Pharmacology & Therapeutics ·Chandrasekhar Udata,Marlynne Micalizzi,Arie Katz,Q GIORGIO,Xiao-Fei Meng	2006	3
17	Enhanced transport of a novel anti-HIV agent—cosalane and its congeners across human intestinal epithelial (Caco-2) cell monolayers International Journal of Pharmaceutics ·Chandrasekhar Udata,Jignesh Patel,Dhananjay Pal,Elżbieta Hejchman,Mark Cushman,Ashim K. Mitra	2002	28
18	Transport of Cosalane—A Highly Lipophilic Novel Anti‐HIV Agent—Across Caco‐2 Cell Monolayers Journal of Pharmaceutical Sciences ·Dhananjay Pal,Chandrasekhar Udata,Ashim K. Mitra	2000	19
19	Pharmacokinetics, Biliary Excretion, and Tissue Distribution of Novel Anti-HIV Agents, Cosalane and Dihydrocosalane, in Sprague-Dawley Rats Drug Metabolism and Disposition ·Kameswara R. Kuchimanchi,Chandrasekhar Udata,Thomas P. Johnston,Alok K. Mitra	2000	11
20	Synthesis, stereoselective enzymatic hydrolysis, and skin permeation of diastereomeric propranolol ester prodrugs Journal of Pharmaceutical Sciences ·Chandrasekhar Udata,Giridhar Tirucherai,Ashim K. Mitra	1999	18

About Chandrasekhar Udata

Chandrasekhar Udata is a scholar working on Hematology, Immunology and Genetics, having authored 36 papers that have together received 895 indexed citations. Recurring topics across this work include Biosimilars and Bioanalytical Methods (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Pharmaceutical studies and practices (6 papers), Hemophilia Treatment and Research (5 papers), Drug Transport and Resistance Mechanisms (4 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (4 papers), Neuroendocrine Tumor Research Advances (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). The work is most often cited by research in Hematology (260 citations), Oncology (333 citations) and Genetics (99 citations). Chandrasekhar Udata has collaborated with scholars based in United States, United Kingdom and New Zealand. Frequent co-authors include Meng Xu, Arie Katz, O. Vesterqvist, Michael E. Burczynski, Lisa Hickey, Elyssa Ott, David A. Roth, John F. DiJoseph, Michael Recht and Nitin K. Damle. Their work appears in journals such as Blood, Gastroenterology and Journal of the American College of Cardiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact